Diovan Positioned For Growth Following Sales Force Shift, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.
You may also be interested in...
Gleevec Sales Gains May Come From Increased Dosing Compliance
Novartis is hoping to boost sales of its oncologic Gleevec (imatinib) by increasing patient compliance with the daily dosing regimen
Gleevec Sales Gains May Come From Increased Dosing Compliance
Novartis is hoping to boost sales of its oncologic Gleevec (imatinib) by increasing patient compliance with the daily dosing regimen
Novartis Will Stand Tough On Sales Force Size, CEO Costa Says
Potential cuts to competitors' sales forces will give Novartis an opportunity to "leverage that asset," the exec says. Novartis' sales force continues to offer a strong return on investment, he notes.